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Antibody epitope mapping is crucial for understand-
ing B cell-mediated immunity and required for char-
acterizing therapeutic antibodies. In contrast to
T cell epitope mapping, no computational tools are
in widespread use for prediction of B cell epitopes.
Here, we show that, utilizing the sequence of an anti-
body, it is possible to identify discontinuous epitopes
on its cognate antigen. The predictions are based on
residue-pairing preferences and other interface char-
acteristics. We combined these antibody-specific
predictions with results of cross-blocking experi-
ments that identify groups of antibodies with over-
lapping epitopes to improve the predictions. We
validate the high performance of this approach by
mapping the epitopes of a set of antibodies against
the previously uncharacterized D8 antigen, using
complementary techniques to reduce method-spe-
cific biases (X-ray crystallography, peptide ELISA,
deuterium exchange, and site-directed mutagen-
esis). These results suggest that antibody-specific
computational predictions and simple cross-block-
ing experiments allow for accurate prediction of
residues in conformational B cell epitopes.
INTRODUCTION
B cell, or antibody (Ab), epitopes hold the key for understanding
antigenic interactions. They are also instrumental in many appli-
cations such as vaccine design, disease prevention, diagnostics,
and therapy (Yang and Yu, 2009). Correct identification of epi-
topes can reveal the molecular effect of Abs on their antigens
(Ags). It is also potentially useful for biotechnological applica-
tions, e.g., by allowing the use of epitopes as diagnostic re-
agents to replace potentially pathogenic complete Ags or as646 Structure 22, 646–657, April 8, 2014 ª2014 Elsevier Ltd All rightsimmunogens for raising Abs or for vaccination. Existing methods
for identification of B cell epitopes (such as X-ray crystallog-
raphy, pepscan, phage display, expressed fragments, partial
proteolysis, mass spectrometry, and mutagenesis analysis) not
only are expensive, laborious, and time consuming but also fail
to identify many epitopes (Xu et al., 2010). Moreover, many of
these methods typically identify linear stretches as epitopes,
while, arguably, most of the epitopes on protein Ags are confor-
mational and even discontinuous. While X-ray crystallography is
maybe the most reliable technique for epitope identification (Sun
et al., 2011), it is expensive, time consuming, and very difficult to
apply for many targets. Recently, deuterium exchange mass
spectrometry (DXMS) has been used to identify epitopes (Coales
et al., 2009; Malito et al., 2013; Obungu et al., 2009; Pandit et al.,
2012; Zhang et al., 2011a); however, this technology, which has
thus far beenmastered only by a handful of laboratories, requires
advanced expertise and expensive equipment. Moreover, the
performance of this technology in the task of epitope mapping
has not been systematically assessed to determine the false-
positive and false-negative rates.
For over 30 years, researchers have tried to predict Ab epi-
topes (Hopp and Woods, 1981). Broadly speaking, current pre-
diction approaches attempt to predict the location of epitopes
based on the presence of features associated with Ab binding
sites, such as hydrophilicity and protrusion from the surface of
the Ag (Ambroise et al., 2011; Ansari and Raghava, 2010;
Kulkarni-Kale et al., 2005; Liang et al., 2009, 2010; Ponomarenko
et al., 2008; Rubinstein et al., 2009a, 2009b; Sun et al., 2009;
Sweredoski and Baldi, 2008; Zhang et al., 2011b). While tools
for T cell epitope prediction are commonly used to guide exper-
imental studies (Vita et al., 2010), existing Ab epitope prediction
methods are not widely used, and several independent assess-
ments have concluded that most of them are not sufficiently
accurate to be of much practical value (Blythe and Flower,
2005; Ponomarenko and Bourne, 2007).
The comparison of Ab and T cell epitope predictionmethods is
instructive, as the success of the latter is due to a key difference:
commonly utilized T cell epitope prediction methods do not
examine Ags for general features associated with T cellreserved
Figure 1. Epitope Prediction Performance for Published 3D Struc-
tures of Ab:Ag Complexes
The figure depicts a PRC. The performances of the per-residue approach, the
patch-per-Ab approach, and the EPSVR method are shown in green, red, and
orange dots, respectively. The random precision is shown as a black line. Note
that the leftmost dot of the PRC for the EPSVR predictions corresponds to the
highest score that can be obtained from the EPSVR website, corresponding to
its highest possible precision.
See also Figure S1 and Tables S1 and S6.
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Antibody-Specific Epitope Mappingrecognition. Rather, different predictions are made, which are
dependent on the specific major histocompatibility complex
(MHC) molecule binding and presenting the epitope to T cells
(Liang et al., 2010).We hypothesized that a similarly more restric-
tive approach can be useful in predicting Ab epitopes and pro-
pose a paradigm shift: instead of asking what parts of an Ag
can be bound by any Ab induced by this Ag, we propose to pre-
dict the epitope of a given Ab using that Ab’s sequence and to
identify a surface patch on the Ag that has complimentary fea-
tures to that specific Ab.
It has been shown that protein-protein interfaces differ in their
characteristics (e.g., amino acid composition) from the rest of the
protein surface (Chakrabarti and Janin, 2002; Jones and Thorn-
ton, 1997a, 1997b; Keskin et al., 2008; Lo Conte et al., 1999;
Ofran and Rost, 2003), allowing their a priori identification from
structure and even from sequence (de Vries and Bonvin, 2008;
Ofran, 2009). B cell epitopes, however, are virtually indistinguish-
able from Ag surface residues in general (Kringelum et al., 2013;
Kunik and Ofran, 2013; Lollier et al., 2011), hampering identifica-
tion based on their intrinsic characteristics (Kringelum et al.,
2013; Ponomarenko and Bourne, 2007). However, the propen-
sity of a certain type of amino acid to contact another amino
acid is different in Ab:Ag interfaces from the propensity in other
protein-protein interfaces (Kunik and Ofran, 2013). These prefer-
ences could not help in identifying epitopes in general, but they
may help in determining whether a given Ab with a given set of
complementary determining regions (CDRs) is likely to bind a
certain epitope.
Clearly, incorporation of relevant experimental data into the
prediction scheme is expected to improve the predictions. This
is particularly appealing in cases where it is possible to use re-
sults that are easy to obtain and do not require laborious and
expensive procedures. Our suggested approach of predicting
Ab-specific epitopes lends itself to such incorporation with
experimental results of a cross-blocking assay between all Abs
of a given Ag. While other epitope prediction methods cannot
straightforwardly utilize such data to improve predictions, theseStructure 22data can be readily applied to the approach we suggest here and
dramatically improve the prediction of epitopes.
Here, we present an Ab-specific epitope prediction approach
and show its performance for a representative set of Ab:Ag
complexes. We then apply this approach to predicting epitopes
in the D8 protein of the vaccinia virus (VACV), a prominent target
of neutralizing Abs elicited by the smallpox vaccine. Using
several different experimental methods, we mapped four
different epitopes for 12 Abs of this Ag. While our computational
method performs better than one of the best state-of-the-art
classic epitope prediction methods, additional increase in the
prediction performance was achieved by incorporating experi-
mental cross-blocking results. Unless otherwise specified, we
use the terms ‘‘mapping’’ or ‘‘identification’’ to refer to experi-
mental characterization of residues or patches that contact the
paratope. The term ‘‘prediction’’ refers to computational sugges-
tion of epitopic residues.
RESULTS
Derivation of an Ab-Specific Epitope Prediction
Algorithm
We set out to determine what properties are associated with
Ab:Ag interfaces. We extracted all structures of Ab:Ag com-
plexes from the Protein Data Bank (PDB) and compiled a nonre-
dundant set of 120 structures (Experimental Procedures; Table
S1 available online). For a given Ab:Ag complex in this set, we
identified all possible pairs of residues in the CDRs of the Ab
and on the surface of the Ag. Of the total 1,779,229 pairs of
CDR:Ag surface residues, 6,605 are in contact and 1,772,624
(99.6%) are not. Using this data set of interface residues, we
could identify properties associated with Ab:Ag residues that
are in direct contact versus those that are not. In addition, the
preference of a certain amino acid to bind another amino acid
was assessed based on their respective propensities in the
Ab:Ag interface residues data set (Experimental Procedures;
Figures S1A and S1B). Next, we trained the ‘‘Random-Forest’’
(RF) machine-learning algorithm (Breiman, 2001) to predict the
propensity of a given residue in an Ab CDR to contact a given
residue on the Ag surface, based on the properties of those
residues (Experimental Procedures; Figure S1C). For each Ag
residue, the features included surface accessibility, secondary
structure, predicted disorder, predicted interaction hotspots,
the amino acid considered, and amino acids neighboring in
sequence. For each Ab residue, the features included the loca-
tion in the Ab (given as heavy or light chain; CDR 1, 2 or 3; and
the residue position within the CDR), the amino acid considered,
and amino acids neighboring in sequence. Finally, the likelihood
of the Ab and Ag residues to pair up (based on the contact poten-
tial; Experimental Procedures; Figures S1A and S1B) is consid-
ered as a feature as well. It is important to note that all these
features can be calculated from the sequence of the Ab and
Ag and do not require 3D structure.
The RF model assigns a ‘‘pair score’’ to each CDR:Ag residue
pair, ranging from 0 (pairs confidently predicted not to bind) to 1
(pairs confidently predicted to bind). For each Ag residue, its
highest pair score was considered as the ‘‘residue score’’ (RS),
representing its predicted probability of being in contact with
any of the Ab residues (i.e., to be in the epitope). Figure 1 shows, 646–657, April 8, 2014 ª2014 Elsevier Ltd All rights reserved 647
Figure 2. Cross-Blocking of D8 Abs
Black cells correspond to Abs that block D8 binding of each other and are thus
assumed to share overlapping epitopes. Gray cells correspond to Abs that
partially blocked each other. Empty cells correspond to Abs that did not affect
theD8binding of eachother. The four groupsof Abs are indicatedby redboxes.
See also Table S2.
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Antibody-Specific Epitope Mappinga precision-recall curve (PRC) evaluating the performance of this
‘‘per-residue’’ prediction approach in green. Every point repre-
sents the precision and recall of the prediction at a given RS
cutoff (Experimental Procedures). The PRC shows the typical
tradeoff between these two measures, where higher precision
is obtainable at the expense of lower recall and vice versa. The
precision of the prediction is consistently above random, indi-
cated by a black line in Figure 1.
As a reference, we also calculated the PRC for EPSVR (Fig-
ure 1, orange), an epitope prediction method recently shown to
represent the best state-of-the-art structure-based epitope pre-
diction methods (Ambroise et al., 2011; Liang et al., 2010; Yao
et al., 2013; Zhang et al., 2011b). The per-residue approach out-
performs EPSVR, particularly in the range of high precision.
While EPSVR requires knowledge of the Ag 3D structure, the
per-residue approach outperforms it in a mode of operation
that does not require it. Thus, while the improvement may
seem small, it actually allows for much wider applicability for
any Ag that was not solved experimentally. Moreover, about
20% of the Ab:Ag complex structures in the test set were
included in the EPSVR training set (while none of them were
included in the training set of the per-residue approach). It is
important to note that this traditional prediction method does
not take into account the Ab sequence for which a prediction
is made; thus, its task is inherently different. Nevertheless, juxta-
posing these PRC graphs demonstrates the contribution of the
information found in the Ab sequence.
To further improve our prediction method, we took advantage
of the fact that epitope residues are not randomly scattered
along the primary protein sequence but are rather clustered
together on the 3D surface of an Ag. This may improve the pre-
cision by allowing the identification of predictions that are clus-
tered together in patches on the protein surface. Technically,
we incorporated this into our prediction approach by computing
a ‘‘patch score’’ (PS) of a given Ag residue, which simply aver-
aged its RS with that of its four closest neighboring surface res-
idues. The PS was used to select the best five-residue patch for648 Structure 22, 646–657, April 8, 2014 ª2014 Elsevier Ltd All rightseach Ag, and each residue within this patch was predicted to be
in contact if its RS was above a selected cutoff score. The size of
the patch affects the precision and recall of the predictions. To
achieve high precision, we selected a patch size of five residues.
A larger patch size would result in a higher recall and lower pre-
cision, as demonstrated in Figure S1D. The PRC of this ‘‘patch-
per-Ab’’ approach is shown in Figure 1, in red. For a given recall,
the corresponding precision of the patch-per-Ab approach was
higher than that of the per-residue approach and that of EPSVR.
As expected, the prediction performance is better for small Ags
(<100 amino acids) than for large ones (>400 amino acids), while
this effect of Ag size is diminished as the precision is increased
(Figure S1E). We further evaluated the prediction performance
by applying the algorithm to an external test set of all Ab:Ag com-
plexes that were solved after the algorithm was generated and
that are not similar to any of the Ags in themain data set (22 com-
plexes). The performance on this external test set was similar to
that of the main test set (Figure S1F).
For subsequent predictions, we used the patch-per-Ab
approach and selected an RS cutoff of 0.43; i.e., only residues
of the best patch of an Ab:Ag complex, which have an RS >
0.43, are predicted to be in the corresponding epitope. This RS
cutoff score corresponds to a recall of 0.05 and a precision of
0.26 and was selected since the precision decreased signifi-
cantly for lower RS cutoff scores. Recall of 0.05 at the residue
level is large enough to provide at least one correctly predicted
epitope residue for 43% of the Ab:Ag pairs in the data set.
Thus, for 43% of the Ags in the data set, residues in the highest
scoring patch were part of the epitope.
Practical Application of the Prediction Algorithms to the
VACV Ag D8
As part of the National Institutes of Health immunomics roadmap
(Sette et al., 2005), we have worked on identifying epitopes
recognized by Abs elicited by the smallpox vaccination. To test
the performance of the prediction algorithms in a practical appli-
cation, we utilized a set of murine monoclonal Abs (Meng et al.,
2011) specific to the D8 Ag in the VACV, the active component of
the smallpox vaccine. D8 is a VACV surface protein targeted by
neutralizing Abs, and we were not aware of any epitopes map-
ped in this Ag as our study began. This makes D8 a biologically
relevant and truly blind test case for our prediction method. We
sequenced each Ab and found that several Abs isolated from
the same animal had highly related sequences, presumably
because they had common progenitors. Using the CDR predic-
tion approach from Kunik et al. (2012a), we found that our panel
contained Abs with 12 combinations of CDRs (Table S2). Using
cross-blocking assays, we found that the Abs cluster into at least
four distinct groups (Figure 2), so that Abs of the same group
show the same pattern of cross-blocking for all Abs in the other
groups and thus are assumed to share the same, or very close,
epitopes. Abs in groups I, II, and IV do not block each other’s
binding. However, Abs from group III can block the binding of
group II and IV Abs, which may be explained by partially overlap-
ping binding regions or by adjacent epitopes that cause steric
hindrances. This panel of Abs and experimental information rep-
resents a typical starting point for an epitope mapping study.
Therefore, we utilized it in combination with our prediction
approach (discussed later).reserved
Figure 3. Projection of the Patch-per-Group Predictions on the D8
Structure
Predicted residues are presented as sticks. The N0 and C0 termini are labeled.
See also Table S3.
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First, we predicted the epitopes of all anti-D8 Abs using EPSVR.
We then used the patch-per-Ab approach described earlier to
provide Ab-specific predictions. Finally, we integrated the
cross-blocking results into our predictions using a ‘‘patch-per-
group’’ approach. In this approach, the cross-blocking data
are used on two levels. First, we divide the Abs into groups, so
that all the Abs in one group cross-block each other. We then
predict one patch for each group, as all Abs in a group are
assumed to bind the same (or a very similar) epitope. This is
done by generating an ‘‘average epitope’’ for the group, where
each residue is scored by averaging the raw residue score for
that residue over all Abs in the group. Then, the clustering
method described in the patch-per-Ab approach is applied to
the ‘‘average epitope,’’ resulting in a set of putative patches for
each group, ranked by their score (see Experimental Procedures
for details). This way, residues that are predicted to have a high
score for several Abs within one group are preferred over those
that have a high score for fewer Abs. The second level utilizes in-
formation from Abs that belong to different cross-blocking
groups: Abs from two groups that did not cross-block each
other’s binding are unlikely to bind residues that are close in
space (let alone the same residue), while Abs from two groups
that partially cross-block each other are unlikely to bind distant
residues. Importantly, we prioritize the groups of cross-blocking
Abs according to the number of Abs in each group.We first make
a prediction for the group with the highest number of cross-
blocking Abs, as it is the group for which we have more indepen-
dent pieces of experimental evidence and thus it is expected to
yield the most reliable predictions. Then, we make a prediction
for the groupwith the second largest number of Abs, by selectingStructure 22the predicted patch with the highest score from among the
patches that agree with the cross-blocking results. This is
done repeatedly for all groups, so that the newly predicted patch
is in agreement with all selected patches of the previous groups.
Figure 3 presents the projection of the residues predicted by
the patch-per-group approach on to the D8 structure (the pre-
dicted residues of each group are also listed in Table S3).
Analyzing these results structurally suggests that the epitopes
for group II and group III Abs overlap substantially. As shown
in Figure 2, Abs from groups II and III partially blocked each
other. The cross-blocking results also show that group IV Abs
partially blocked group III but did not block group I Abs. How-
ever, the patch predicted for group IV does not seem to be closer
to the patch predicted for group III than to the patch predicted for
group I. This may suggest that the actual epitope of group III (and
not of group II) extends beyond the predicted residues toward
the predicted patch for group IV.
Experimental Epitope Mapping of Anti-D8 Abs
To map epitopes of the Abs in our test set, we first performed
ELISAs using 20-mer peptides overlapping by 10 residues and
spanning the D8 Ag (i.e., sliding window of 20 positions with
step size of 10). The results are shown in Figure 4A: Abs from
both group II and group III recognized a linear peptide spanning
residues 91–110. A significantly higher signal was obtained for
group II Abs. Truncation analysis of the peptide showed that the
binding site was contained in residues 93–110 (data not shown).
To fine-map the binding site, we performed alanine substitutions
of peptide 93–110 and tested peptides with substitutions for their
ability to block the binding of the Abs to the wild-type peptide
91–110. As shown in Figure 4B, this revealed two distinct binding
patterns for the group II Abs versus the tested group III Abs.
Next, we performed crystallization trials with Abs from all
groups. For the group IV Abs, we succeeded in determining a
high-resolution structure of the LA5Ab in complexwith theD8pro-
tein, alongwith apo structures of the D8Agand the LA5Ab (Matho
et al., 2012). The solved crystal structure of the D8:LA5 complex
allowed us to locate the 93–110 peptide and its alanine scanning
results, relative to group IV epitope, in the 3D space (Figure 4C).
The residues important for the binding of groups II and III Abs are
clustered into two intersecting regions, suggesting two partially
overlapping epitopes. This is in agreementwith the cross-blocking
results, according towhich these two groups of Abs compete with
each other. Moreover, the residues important for group III Abs are
closer to the LA5 binding site than those important for group II.
Indeed, two of the three residues that are important for group III
but not for group II Abs binding (Y104 and K108) are also included
in the group IV epitope. This provides an explanation of why group
IV Abs compete with group III but not with group II Abs, while both
group II and III Abs bound the same linear peptide.
Finally, we performed deuterium exchange experiments with
the JE11 Ab (group I), for which none of the other methods suc-
ceeded in revealing the epitope (Experimental Procedures). Fig-
ure 4D shows that the regions corresponding to residues 10–14
and 80–90 have the most slowing of deuterium exchange in the
presence of group I Ab (an average slowdown over the three time
points of 24.1%and 23.3%, respectively). As shown in Figure 4E,
these two linear sequence regions come together in the D8 pro-
tein to form a contiguous binding surface., 646–657, April 8, 2014 ª2014 Elsevier Ltd All rights reserved 649
(legend on next page)
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Antibody-Specific Epitope MappingValidation of Identified Epitopes Using Site-Directed
Mutagenesis
To further confirm the epitopes we have identified, we produced
13 variants of D8 in which individual residues weremutated to an
alanine and tested how these single amino acid substitutions
affected the binding ability of one representative Ab per group
in ELISAs. The binding of these variants and their location are
shown in Figures 5 and S2. Eleven variants were picked based
on the mutated residue being in the epitopes as inferred from
the experimental epitope mapping. Six of these variants indeed
showed a significant drop in binding of all Abs of the group that
binds the epitope that includes the mutated residues, but not in
binding of Abs from other groups, emphasizing the role of these
residues in Ab binding. Three variants did not affect binding of
any of the Abs, despite the fact that the residues were spatially
located within the respective binding sites. Finally, two variants
(Y101A and E106A) showed little binding for any of the Abs, sug-
gesting that the mutations may have misfolded the proteins or
hampered their stability. Two additional mutants (K211A and
D25A), which were not mapped to any of the four epitopes,
were picked as a negative control and indeed did not affect D8
binding to any of the tested Abs. Overall, these data confirm
our epitope mapping results and provide additional details on
which residues contribute most to the binding affinity.
Evaluation of Prediction Performance for Anti-D8 Abs
Figure 6A indicates the predicted epitopes together with the epi-
topes we identified experimentally (Experimental Procedures;
Table S4). The epitope of group I covers all five residues in the
predicted patch of that group. The epitope of group IV covers
two of the four predicted residues for this group. The 93–110
peptide, which represents group II and III epitopes, covers all
four residues predicted for group II and three of the four residues
predicted for group III. The one residue from group III not
included in the 93–110 peptide is D112 (dark blue). Mutation of
D112 to alanine suggests that it affects the binding of group II
Abs (Figure 5A) but does not affect the binding of Abs from group
III or any of the other groups.
We evaluated our D8 epitope predictionsmadewith the patch-
per-Ab and patch-per-group strategies and EPSVR in a quanti-
tative fashion as well. Figure 6B shows that the use of competi-
tion binding data leads to a better recall as well as precision and,
ultimately, to the elimination of most false-positive predictions.
For further evaluation of the patch-per-group approach, we
applied it to lysozyme, since it has the largest number of solvedFigure 4. Experimental Epitope Mapping
(A) ELISA assessment of D8 peptides binding to the Abs. Peptide 91–110 (red box
based on duplicate values.
(B) Alanine scan for peptide 93–110. Residue positions that, when substituted for
residue positions that reduced but did not abrogate binding (gray cells), and p
represents group II Abs, and the lower red rectangle represents group III Abs. Up
binding, and lower arrows indicate positions that were important only for group
(C) 3D structure of D8 bound to LA5 Ab (group IV). Residues that abrogated bindin
(middle). Residues that exclusively affected binding of Abs from one group but no
binding of either group II or group III Abs are highlighted in cyan. The group IV epit
representation.
(D) Differences in deuteration levels in the presence compared to absence of Ab b
faster exchange is marked in red. Residues 10–14 and 80–90 (black box) show t
(E) The 10–14 and 80–90 peptides are shown in orange and red, respectively, on
Structure 22structures bound to different Abs. This allowed us to divide the
nine Abs that bind the lysozyme into four groups based on the
spatial location of their epitopes on the lysozyme surface. To
apply the patch-per-group approach, we assumed that Abs
within each of these four groups are likely to cross-block each
other based on their relative location. We found that the patch-
per-group approach resulted in an almost 2-fold increase in
precision over the patch-per-Ab approach, similar to the
improvement observed for D8 (Table S5). While the transforma-
tion from the multiple X-ray structures to the ‘‘assumed’’ cross-
blocking matrix is not trivial, this provides another example for
the power of using several Ab-specific predictions together
with competition data to improve performance.
DISCUSSION
The present study evaluates an Ab epitope prediction approach
on both a comprehensive data set of crystal structures from the
PDB and a set of Abs targeting the VACV D8 protein. For the
latter, we have combined multiple experimental approaches to
map epitopes and validate the predictions. Linear peptide
epitope mapping studies are often criticized for missing confor-
mational epitopes and, therefore, introducing bias in the space of
known epitopes. However, crystallization trials of Ab:Ag com-
plexes also often fail for various reasons. This might also intro-
duce biases when relying solely on epitopes identified in crystal-
lization studies. To reduce bias, it is necessary to map the
epitopes of all Abs for a given target, as we demonstrated here
by using multiple experimental approaches. We suggest that
this experimental approach of combining multiple epitope map-
ping techniques is advantageous over any single approach, as
different techniques succeed for different Abs, and the informa-
tion gained from different experiments complement each other
to gain a fuller understanding of Ab:Ag interactions.
The current standard approach to B cell epitope prediction is to
scan an Ag for determinants that possess physicochemical or
structural traits similar to thoseobserved in knownepitopes. Inde-
pendent benchmark studies have concluded that the perfor-
mance of tools based on this approach is not impressive (Blythe
andFlower, 2005;PonomarenkoandBourne, 2007).Several tech-
nical and computational limitations have been suggested to
explain the poor performance of this standard approach (Green-
baum et al., 2007; Ponomarenko and Bourne, 2007). These
methods attempt to predict the epitopes on a given Ag for any
Ab. However, almost any residue on the Ag surface may be a) bound group II and III Abs but not group I and IV Abs. Error bars indicate SEMs
alanine, abrogated binding of the peptide to the corresponding Ab (black cells),
ositions that had no effect on binding (empty cells). The upper red rectangle
per arrows indicate peptide residues that were important only for group II Abs
III Abs binding.
g in alanine scan are shown in green for group II (left) and dark blue for group III
t the other are circled. Residues of the 93–110 linear peptide that did not affect
ope residues are colored orange (right). The LA5 Ab is shown in a yellow ribbon
inding at four time points. Slower deuterium exchange is marked in blue, and a
he most marked slowing.
the D8 structure.
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Figure 5. Site-Directed Mutagenesis
(A) Summary of all titration curves. Half maximal inhibitory concentration (IC50) values were extrapolated using the Prism Software package. The bar graphs
indicate the fold change in IC50 value for a given mutant protein and a given Ab compared to the median IC50 values of that Ab/mutant protein, as calculated by
median polishing. For example, the group I Ab JE11 has an IC50 value of 17 ng/ml for themutant E11A, while itsmedian IC50 value over all themutant andwild-type
measurements is 3 ng/ml, which is an6-fold difference. Mutated residues that were mapped to the epitope of group I, II + III, and IV Abs are shown as dark red,
green, and orange bars, respectively. Mutated residues that were not mapped to any of the epitopes are shown as black bars.
(B) The mutated residues in the context of the D8 structure. Epitope residues of group I (inferred from the DXMS assay), group II and III (inferred from the ELISA),
and group IV (as observed in the D8:LA5 crystal structure) are colored red, dark green, and orange, respectively. Y104 and K108, which are common to the group
IV epitope and the 93–110 peptide (group II and III epitopes), are colored light blue. The mutated residues are shown in ball-and-stick representation. K211 is not
shown as it is disordered in the D8 crystal structure.
See also Figure S2.
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Antibody-Specific Epitope Mappingpart of anepitopeof someAbs. (Benjaminet al., 1984;Greenbaum
et al., 2007; Novotny´ et al., 1986; Thornton et al., 1986). Thus,
manyof the false-positivepredictionsof this approachmight actu-
ally be epitopic residues of an Ab that is yet to be characterized
(Sela-Culang et al., 2013). This is especially truewhen only a small
number of Abs of a certain Ag are available. The alternativemeth-
odology we suggest here is based on earlier studies of the Ofran
lab, which suggested a change of perspective: rather than classi-
fyingAg residuesapriori asepitopicornonepitopic,wepredict the
potential match between a given Ab and a given epitope.
We improved performance by incorporating structural infor-
mation to define epitopes as residue patches on the Ag (the
patch-per-Ab approach). The most significant improvement in
prediction performance was achieved by including the experi-
mental cross-blocking data and making predictions for groups
of Abs (the patch-per-group approach). While the cross-block-
ing data were required in order to reach the high performance
showed in the D8 case, the experimental cross-blocking results
themselves (without the computational method) are not of much
use for epitope mapping. Moreover, the cross-blocking data
could be utilized only with a computational method that predicts
an epitope of a given Ab (as opposed to the ‘‘classical’’ approach
that predicts an epitope for any Ab). Thus, it is the combination of
the Ab-specific epitope prediction approach and the cross-
blocking experiment that allowed for this performance.652 Structure 22, 646–657, April 8, 2014 ª2014 Elsevier Ltd All rightsOne of the features we used to train the machine learning is an
amino acids pairing preferences matrix (Figures S1A and S1B).
While many amino acids showed high preferences for other
amino acids of the same type (e.g., hydrophobic-hydrophobic)
or of opposite charge (e.g., positive-negative), there are also
some preferences of hydrophobic amino acids for hydrophilic
ones. Such preferences in Ab:Ag recognition have been
mentioned in the past (Blalock and Bost, 1986; Blalock and
Smith, 1984; Bost and Blalock, 1989).
One limitation of our method is that it only allows us to predict
patches of amino acid residues that are likely to be located within
a discontinuous epitope recognized by a given Ab of known
sequence. This does not amount to an accurate identification
of the entire epitope, which typically consists of many more res-
idues that contribute to its overall antigenic or immunogenic
specificity. How would these patches be useful for the design
of diagnostic tools and vaccines? We may consider the pre-
dicted patch as an ‘‘anchor’’ to the entire epitope. This anchor
may be then used as a starting point for revealing the rest of
the epitope. For example, mutating several residues near the
anchor but in different directions may lead to the right direction
to which the anchor extends. Furthermore, the cross-blocking
data may sometimes provide additional information in this
regard. In the D8 case, for example, both group II and III Abs
shared partially overlapping anchors, while only group IIIreserved
Figure 6. D8 Epitope Prediction Evaluation
(A) Qualitative evaluation: the observed epitope
of group I (inferred from the DXMS assay),
group II and III (inferred from the ELISA), and
group IV (as observed in the D8:LA5 crystal
structure) are colored red, dark green, and
orange, respectively. D112, which is considered
a part of group II epitope based on the muta-
genesis results, is colored dark blue. Y104 and
K108, which are common to the group IV epitope
and the 93–110 peptide (group II and III epitopes),
are colored light blue. The predicted residues
based on the patch-per-group approach are
shown as sticks, while all other residues are
shown as lines.
(B) Quantitative evaluation: The percentage of
the predicted residues that are, indeed, in the
epitope (true-positive), those that are likely to be
in the epitope, and those that are not in the
epitope (false-positive) are represented in dark
green, light green, and red bars, respectively (see
Experimental Procedures for the different definitions). The percentage of epitope residues predicted as such (recall) is indicated with black dots. Results
are shown for predictions made with the patch-per-Ab and patch-per-group approaches and with the EPSVR method.
See also Tables S4 and S5.
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assumption would be that the epitope of group III Abs is further
extended toward that of group IV, while the epitope of group II is
extended to a different direction.
Another limitation is that our epitope predictions in their cur-
rent form are not immediately applicable to identify either poten-
tial diagnostic reagents or immunogens capable of inducing a
broad immune response, as in both cases, it is not a single bind-
ing specificity found in one Ab that is relevant but a variety of
different Ab molecules that may be implicated. Instead, our
methodology is primarily relevant to identifying the epitopes of
existing sets of monoclonal Abs. There are, however, scenarios
in which the identification of the binding site of one Ab is impor-
tant. For example, in studying the effect of a broadly neutralizing
Ab or using such Abs to design a general vaccine, one would
want to identify the epitope of that specific Ab. Similarly, the at-
tempts to develop monoclonal Abs for various applications often
require the mapping of specific epitopes. Moreover, we believe
that our approach may also constitute an important step toward
more general design of diagnostic reagents and immunogens,
which can, for example, be achieved by scaling up the number
of Ab sequences considered based on next-generation
sequencing and expanding the prediction approach by inte-
grating this information. Future studies will need to experimen-
tally validate that this will be feasible.
Our Ab epitope prediction approach performs better than ex-
isting approaches but also requires additional experimental data
to be applicable. Existing Ab epitope prediction approaches only
require the Ag sequence and/or structure as an input. In addition,
our approach requires the sequence of the binding Ab. Current
sequence information is available nearly exclusively for Abs
with a known crystal structure. This is probably due to the
historic difficulty of determining Abs sequences with standard
sequencing techniques due to the variability of the Ab coding
genes. This has been only recently overcome by the emergence
of sequencing approaches using Ab primer cocktails (Casellas
et al., 2007; Ehlers et al., 2006;Wang et al., 2000). Thus, the avail-Structure 22ability of Ab sequences should no longer be a bottleneck for
future prediction studies. To fully take advantage of the
approach, the 3D structure of the Ag is also needed, as well as
a set of Abs and their cross-blocking pattern. For the 3D struc-
ture, since both the secondary structure and surface accessi-
bility features can be predicted from sequence, the per-residue
approach is readily applicable to any Ag, even when there
is no experimentally determined 3D structure available. The
patch-per-Ab and patch-per-group approaches, which take
into account the spatial location of the Ag residues, require an
experimentally determined 3D structure of the Ag or of a close
homolog. For the availability of sets of Abs and cross-blocking
data, all studies that we are aware of, aimed at producing mono-
clonal Abs against a target, start out with a set of candidate Abs
that is subsequently narrowed down to candidates with themost
desirable properties. It should, therefore, be possible in most
studies to generate cross-blocking data and to sequence Abs,
even if the epitope from only one Ab is of interest. Thus, our
approach for Ab epitope prediction is applicable to most prac-
tical applications where a set of Abs for a target has already
been generated.
Several possible avenues exist to further improve the predic-
tion quality of an Ab-specific binding prediction approach. First,
it will likely be possible to improve prediction performance by
optimizing the specificmachine-learning algorithm approach uti-
lized and by adding to the features used to determine whether or
not a given Ab:Ag residue pair is in contact. The data set included
in the present study provides a benchmark set for others to
develop and evaluate such potential improvement in methodol-
ogy. Second, a current bottleneck is the availability of high-qual-
ity experimental data. The most valuable data are fully resolved
3D structures of Ab:Ag complexes. When we assembled our
data set from the PDB, there were 646 complexes of Ags with
human or murine Abs available. However, only 120 complexes
had unique Ab:Ag pairs. This means that, on average, each
Ab:Ag combination is represented by more than five experimen-
tally determined structures. To truly understand Ab:Ag contact, 646–657, April 8, 2014 ª2014 Elsevier Ltd All rights reserved 653
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relevance are needed. This call for more representative struc-
tures is similar to the needs identified in the structural genomics
initiative (Burley et al., 1999). While it is unlikely that a plethora of
new Ab:Ag crystal structures will be available in the near future,
simply because crystal structures remain very hard to obtain, a
realistic near-term goal is that the amino acid sequences of
monoclonal Abs with known epitopes are published as part of
their characterization and are thereby deposited in the Immune
Epitope Database (Vita et al., 2010).
Finally, while the patch-per-Ab approach was optimized using
a training set and tested on an independent test set, the patch-
per-group approach could not be trained and tested in a similar
way, since we are not aware of systems in which the cross-
blocking data of different Abs, aswell as their epitopes on a com-
mon Ag, are known. Instead, the patch-per-group procedure
was built based on a simple logic and applied for the D8 case
study, followed by experimental mapping of the different epi-
topes. Thus, some parameters, such as the Abs grouping proce-
dure, may have been done differently. For example, group III
appears to be composed of two subsets of Abs, where the
Abs in each subset completely cross-block each other but only
partially cross-block the Abs in the other subset. The likely struc-
tural interpretation is that there are two overlapping epitopes. By
grouping these two subsets together, we allow a more accurate
identification of the residues that are common to both of these
epitopes. This gives us higher precision for the residues we iden-
tify. When more cases with available cross-blocking and epi-




A nonredundant data set of Ab-Ag structures from Burkovitz et al. (2014) was
used. Briefly, a list of 646 human and mouse Ab:Ag X-ray structures was ex-
tracted from IMGT/3Dstructure-DB (version 4.5.0) (Lefranc et al., 2010), and
the structures were downloaded from the PDB website. Abs sequences
were clustered using BLASTCLUST (Dondoshansky andWolf, 2002), requiring
97% sequence identity and 95% coverage. A representative from each of the
resulting clusters was selected based on the following criteria. First, the struc-
ture with fewest in vitro modifications was selected. Then, the structure with
the longest Ag, and then the structure with the better resolution, was preferred.
Structures with Ags of fewer than 65 amino acids were not included. The final
data set contained 120 Ab:Ag complexes.
The data set was divided into three subsets for 3-fold cross-validation. CD-
HIT (Li and Godzik, 2006) was used to cluster all structures, with Ag sequence
identity >70%. Structures of the same cluster were assigned to the same
subset. Thus, different Abs with the same Ag were not used both to train
and to test a single RF model. The structures in each of the three subsets
are listed in Table S1.
RF Model Generation
Applying the 3-fold cross-validation approach, we generated three comple-
mentary RF models, each trained on two subsets and tested on the third.
For each of the structures in the training set, all pairs of residues—one from
the Ab CDRs and one from the Ag surface—were extracted. The CDRs
were defined using PARATOME (Kunik et al., 2012a, 2012b) in a mode of
operation that requires only the sequence of the Ab. DSSP (Kabsch and
Sander, 1983) was used to calculate the solvent accessibility of each of the
Ag residues, and residues with a solvent accessibility >0 were defined as sur-
face residues. For each pair of residues, the following features were extracted
or calculated.654 Structure 22, 646–657, April 8, 2014 ª2014 Elsevier Ltd All rights1. The paired amino acid on the Ag, four amino acids N terminal to it, and
four amino acids C terminal to it.
2. The paired amino acid on the Ab, four amino acids N terminal to it, and
four amino acids C terminal to it.
3. The relative solvent accessibility of the Ag residue. The DSSP value
was divided by the theoretical maximal solvent accessibility of that
amino acid.
4. The secondary structure of the Ag residue as calculated by DSSP
(helix, strand, or loop).
5. The Ab chain (heavy or light).
6. The CDR number (1, 2, or 3).
7. The position of the Ab residue in its CDR (1 for the residue on the N-ter-
minal end of the CDR).
8. The predicted disorder state of the Ag residue (disordered or not, as
calculated by MD [Schlessinger et al., 2009]).
9. The predicted classification of the interaction hotspot for the Ag resi-
dues (a hotspot or not, as calculated by ISIS [Ofran and Rost, 2007]).
10. A pair contact potential representing the potential for the interaction
between the residues at hand, calculated as described later.
Each pair of residues was labeled as positive (i.e., an observed contact) if at
least two of their respective nonhydrogen atoms were within 5Ǻ of each other
or as negative (i.e., not in contact) otherwise. All 10 features of the positive
pairs and of the randomly selected negative pairs, and their classification,
were submitted to a 1,000 trees RF run implemented by R.
Ab:Ag Contact Potential Generation
All Ab:Ag pairs of residues in contact (within a distance of 5 Ǻ) were
extracted from the data set. For each combination of two amino acid
types, i from the Ab and j from the Ag, the pair’s statistical energy Eij was
calculated according to Equation 1, where fij is the number of times the
two amino acids i and j were found to be in contact, fi is the number of times
amino acid i appears in a paratope, and fj is the number of times amino acid j
appeared in an epitope. Since there are almost no cysteines in the Ab para-
topes or methionine in the light-chain CDRs, the E values of all 20 pairs of

















Using the RF Model for Epitope Prediction
The RF model produced a pair-score between 0 (for pairs of residues that are
predicted to not bind) and 1 (for pairs of residues predicted to be a part of the
Ab:Ag interface). This score was used in two different strategies to provide a
final prediction of epitopes. In the per-residue approach, the RS of an Ag res-
idue is defined as the highest pair-score of this residue and is used for predict-
ing individual residues to be in the epitope: for a selected RS cutoff score, all
residues with an RS above this cutoff score are predicted to be in the epitope.
The patch-per-Ab approach incorporates the information of predicted resi-
dues that are close in space by searching for patches of predicted epitope
residues. For each Ag surface residue, the four residues closest in space
were grouped together with it to generate a patch. The PS is defined as the
average RS over all residues within the patch. Since all patches contain five
residues, the PS is comparable. For a given Ab:Ag pair, the patch with the
highest PS was selected, and the residues in this patch were predicted to
be in the epitope if their RS was above a selected cutoff score. If there was
more than one patch with the same PS, the one with the highest single RS
was preferred.
Model Performance Evaluation
Each RF model was trained on two thirds of the available data and tested to
predict the epitope residues of the Ag:Ab pairs in the remaining one third of
the data as a test set. The predictions were combined on the whole set in
order to evaluate the overall prediction performance. PRCs were drawn by












where TP is the number of true-positive predictions, FP is the number of false-
positive predictions, and FN is the number of false-negative predictions.
Random precision was calculated as the number of residues in all epitopes
divided by the number of all Ag surface residues.
The performance of the per-residue and the patch-per-Ab strategies were
compared to that of EPSVR using the EPSVR server (http://sysbio.unl.edu/
EPSVR/) to predict epitopes of all 120 Ags in the data set. A score between
0 and 100 was assigned to each of the Ag residues. The prediction was
assessed with respect to the epitopes in our data set.
Applying the RF Model to D8
All 120 Ag:Ab complexes were used to generate another RF model applied to
D8 and its Abs. Note that no BLAST e-value of less than 0.1 was found be-
tween D8 and any of the Ags in the data set. All pairs of residues, one from
the Ab CDRs and one from the D8 surface, were extracted, and their features
were calculated as described. For the 12 Abs, only their sequence was used to
calculate the features. For D8, the apo X-ray structure (PDB ID 4E9O) was
used. MODELER (Sali et al., 1995) was used to model three residues (N207–
E209) disordered in the crystal structure.
The predictions for D8 were made using the patch-per-Ab and the patch-
per-group strategies described earlier.
In the patch-per-Ab strategy, the patch with the highest PS was
selected, and if two or more patches with the same PS existed, the one
with the single best RS was preferred. As described in the Results section,
residues in the best patch with an RS above 0.43 were predicted to be in
the epitope.
In the patch-per-group strategy, each Ag surface position was assigned a
group residue score (GRS), which is the average of all RSs assigned to this
position by the corresponding Abs in the group. Then the group PS (GPS) is
assigned to each Ag surface residue in complete analogy to the PS. The pre-
dictions were made for one group at a time, ordering the groups by decreasing
number of Abs. First, a prediction wasmade to the group with the largest num-
ber of Abs, then to the second largest group, and so on. In each group, the best
scoring patch was considered first. If it was not in agreement with the cross-
blocking data, (i.e., it overlapped with a selected patch of another group while
the Abs of these two groups do not compete with each other, or alternatively, if
the patch is distant from a selected patch of another group with which it does
compete), the patch was excluded for this group, and the second best patch
was examined, and so on. Residues in the selected patch that have a GRS
above 0.43 were considered as the final prediction.
D8 Prediction Evaluation
For each of the four groups, each Ag surface residue was defined as either ‘‘in
epitope,’’ ‘‘likely in epitope,’’ or ‘‘not in epitope,’’ based on the experimental
data available (see Supplemental Experimental Procedures for details). LA5
is the only Ab for whichwe know the structure of the epitope based on the crys-
tal structure of the Ab:Ag binding site. For the remainder of the Abs, epitopes
were mapped by nonstructural assays, and we determined the residues likely
to be part of the structural epitope as follows: for Ab FH4. One (group IV), we
assumed that its epitope is identical to that of LA5, as they completely block
each other’s binding and show the same pattern in blocking the binding of
all other Abs. For all Abs in groups II and III, we assumed that the residues in
the 93–110 peptide are in the epitope of these Abs. While the cross-blocking
and alanine scanning of the peptide suggests that these two groups have
only partially overlapping epitopes (see Results), these data do not allow us
to determine which residue belongs to which epitope, since a mutation of a
residue that does not affect binding may still be part of the corresponding
epitope. For Abs of group II, we assumed that their epitope includes D112
as well (based on the site-directed mutagenesis data). For Ab JE11 (group I),
we assumed that the epitope includes residues 10–14 and 80–90 (based on
the DXMS data). To make the epitope definition of groups I–III more compara-
ble to the definition of the group IV epitope (and since residues not included in
the ELISA andDXMSpeptidesmay still be in the respective epitopes), residuesStructure 22within a distance of 3 Ǻ of the residues described earlier were included in the
list of putative epitope residues (‘‘likely in epitope’’). Table S4 summarizes the
definitions of each of the four groups.
Applying EPSVR to D8
The EPSVR server provides a score between 0 and 100 for each Ag residue. To
have the most appropriate comparison with our method, we considered for
each Ab:D8 complex, the x best scored residues, where x is the number of res-
idues predicted by the patch-per-Ab approach.
External Test Set Construction
All Ab:Ag crystal structures that were published since May 2011 were
collected. Ab sequences were clustered, and a representative from each clus-
ter was selected as described earlier in the ‘‘Data Set Construction’’ section.
CD-HIT was then used to cluster together all Ags from the main data set and
from the external test set with sequence identity > 70%. Only Ags from the
external test set that were not clustered with Ags from the main data set
were included in the final external test set. One structure (PDB ID code:
3SOB), for which not all CDRs were predicted by PARATOME, was excluded.
The final test set contained 22 Ab:Ag pairs (see Table S6 for the full list of PDB
ID codes).
External Test Set Performance
The prediction performance of the external test set was done in the same way
as for the main data set. The RF model used was the one built using all 120
Ab:Ag pairs of the main data set (the same model used for the prediction of
D8 epitopes). Epitopes were predicted using the patch-per-Ab approach.
Epitope Mapping by ELISA
Overlapping 20-mer peptides for the D8 Agwere synthesized and tested for Ab
binding using an ELISA. Flat-bottomed 96-well microtiter plates were coated
with 100 ml of NeutrAvidin biotin-binding protein (1 mg/ml) diluted in PBS over-
night at 4C (ThermoScientific Pierce). Then, coated plates were washed with
washing buffer (PBS, pH 7.2, plus 0.05% Tween 20) and blocked with blocking
buffer (PBS, pH 7.2, plus 1% BSA plus 0.1% Tween 20) for 2 hr at room tem-
perature (RT). Plates were incubated with 100 ml of overlapping linear bio-
tinylated peptides (200 ng/ml) in blocking buffer for 90 min at RT. Plates
were washed and incubated with purified monoclonal Ab at 10 mg/ml for
90 min at RT. Plates were washed, and the bound Ab was detected by adding
a streptavidin-horseradish peroxidase (HRP)-conjugated secondary antibody
to mouse immunoglobulin G (Invitrogen) and incubated for 60 min at RT,
followed by OPD substrate (Sigma-Aldrich).
Epitope Mapping by Deuterium Exchange
To maximize peptide sequence coverage, the optimized quench and proteol-
ysis condition was determined prior to DXMS experiments (Hailey et al., 2009;
Li et al., 2011). For each sample, 0.5 ml of stock solution of D8 at 4.7 mg/ml was
diluted with 7.5 ml of H2O buffer (8.3 mM Tris-HCl, 150 mM NaCl, in H2O,
pH 7.2) at 0C and then quenched with 12 ml of a quench solution of 0.8% for-
mic acid, 16%glycerol, andGdnHCl at final concentrations of 0.5M and 1.0M.
The samples were then frozen on dry ice and stored at 80C. Procedures for
pepsin digestion from DXMS have been described elsewhere (Burns-Hamuro
et al., 2005) (see Supplemental Experimental Procedures for details).
In addition, nondeuterated samples (incubated in H2O buffer mentioned
earlier) and equilibrium-deuterated back-exchange control samples (incu-
bated in D2O buffer containing 0.5% formic acid overnight at 25
C) were
prepared as described elsewhere (Hamuro et al., 2004; Li et al., 2011) The
centroids of the isotopic envelopes of nondeuterated, functionally deuterated,
and fully deuterated peptides were measured using HDExaminer and then
converted to corresponding deuteration levels with corrections for back-
exchange (Zhang and Smith, 1993).
Cross-Blocking ELISA
Ag was prepared at 0.5 mg/ml and used to coat Nunc Polysorbent flat-
bottomed 96-well plates with 100 ml per well. Plates were incubated overnight
at 4C and washed four times with PBS plus 0.05% Tween 20. We added
100 ml of blocking buffer (PBS + 10% fetal bovine serum) to the plate and incu-
bated it for 90 min at room temperature. Blocking buffer was discarded, and
100 ml of antibodies of interest were added to the plate at 10 mg/ml and incu-
bated for 90 min. HRP-conjugated antibodies of interest (Innova Biosciences
Lightning-Link HRP conjugation kit) were prepared at 0.5 mg/ml and added, 646–657, April 8, 2014 ª2014 Elsevier Ltd All rights reserved 655
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and optical density at 490 nm was read on a SpectraMax 250 (Molecular
Devices).
Peptide Truncation and Alanine Scan
Variant peptides with N- or C-terminal truncations and/or alanine substitutions
were tested for their ability to block binding to their parent 20-mer peptides in
an ELISA. Ninety-six-well plates were coated with 100 ml NeutrAvidin per well
at a concentration of 0.5 mg/ml (see Supplemental Experimental Procedures
for details).
Protein Mutagenesis
D8 variants with single-residue changes to alanine were generated by site-
directed mutagenesis performed directly in the pET22b+ expression vector
using the QuickChange II Site-Directed Mutagenesis Kit (by Agilent) according
to manufacturer’s suggestions. Successful mutations were confirmed by
sequencing (see Supplemental Experimental Procedures for details).
ACCESSION NUMBERS
The Immune Epitope Database accession number for epitope mapping
data reported in this paper is http://www.iedb.org/subID/1000515. The
Genbank accession numbers for the antibody sequences reported in this
article are AGO04750, AGO04761, KF017296, KF017307, KF017295,
KF017306, KF017297, KF017308, KF017304, KF727003, KF017298,
KF017309, KF017299, KF017310, KF017300, KF017311, KF017301,
KF017312, KF017302, KF017313, KF017303, KF017314, JQ815182, and
JQ815183.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
two figures, and six tables and can be found with this article online at http://
dx.doi.org/10.1016/j.str.2014.02.003.
ACKNOWLEDGMENTS
This project has been funded in whole or in part with federal funds from the
National Institutes of Allergy and Infectious Diseases under Contract no.
HHSN272200900048C. Y.O. was supported in part by the Israeli Science
Foundation, grant no. 511/10 (http://www.isf.org.il). We thank Anat Burkovitz
for providing the data set; Shauli Ashkenazy for running the ISIS and MD pro-
grams; and Ariel Feiglin, Vered Kunik, Sivan Goren, and Ahron Brodie for their
helpful comments.
Received: November 6, 2013
Revised: January 23, 2014
Accepted: February 1, 2014
Published: March 13, 2014
REFERENCES
Ambroise, J., Giard, J., Gala, J.L., and Macq, B. (2011). Identification of rele-
vant properties for epitopes detection using a regression model. IEEE/ACM
Trans. Comput. Biol. Bioinformatics 8, 1700–1707.
Ansari, H.R., and Raghava, G.P. (2010). Identification of conformational B-cell
epitopes in an antigen from its primary sequence. Immunome Res. 6, 6.
Benjamin, D.C., Berzofsky, J.A., East, I.J., Gurd, F.R., Hannum, C., Leach,
S.J., Margoliash, E., Michael, J.G., Miller, A., Prager, E.M., et al. (1984). The
antigenic structure of proteins: a reappraisal. Annu. Rev. Immunol. 2, 67–101.
Blalock, J.E., and Bost, K.L. (1986). Binding of peptides that are specified by
complementary RNAs. Biochem. J. 234, 679–683.
Blalock, J.E., and Smith, E.M. (1984). Hydropathic anti-complementarity of
amino acids based on the genetic code. Biochem. Biophys. Res. Commun.
121, 203–207.656 Structure 22, 646–657, April 8, 2014 ª2014 Elsevier Ltd All rightsBlythe, M.J., and Flower, D.R. (2005). Benchmarking B cell epitope prediction:
underperformance of existing methods. Protein Sci. 14, 246–248.
Bost, K.L., and Blalock, J.E. (1989). Production of anti-idiotypic antibodies by
immunization with a pair of complementary peptides. J. Mol. Recognit. 1,
179–183.
Breiman, L. (2001). Random forests. Mach. Learn. 45, 5–32.
Burkovitz, A., Sela-Culang, I., and Ofran, Y. (2014). Large-scale analysis of
somatic hypermutations in antibodies reveals which structural regions, posi-
tions and amino acids are modified to improve affinity. FEBS J. 281, 306–319.
Burley, S.K., Almo, S.C., Bonanno, J.B., Capel, M., Chance, M.R.,
Gaasterland, T., Lin, D., Sali, A., Studier, F.W., and Swaminathan, S. (1999).
Structural genomics: beyond the human genome project. Nat. Genet. 23,
151–157.
Burns-Hamuro, L.L., Hamuro, Y., Kim, J.S., Sigala, P., Fayos, R., Stranz, D.D.,
Jennings, P.A., Taylor, S.S., and Woods, V.L., Jr. (2005). Distinct interaction
modes of an AKAP bound to two regulatory subunit isoforms of protein kinase
A revealed by amide hydrogen/deuterium exchange. Protein Sci. 14, 2982–
2992.
Casellas, R., Zhang, Q., Zheng, N.Y., Mathias, M.D., Smith, K., and Wilson,
P.C. (2007). Igkappa allelic inclusion is a consequence of receptor editing.
J. Exp. Med. 204, 153–160.
Chakrabarti, P., and Janin, J. (2002). Dissecting protein-protein recognition
sites. Proteins 47, 334–343.
Coales, S.J., Tuske, S.J., Tomasso, J.C., and Hamuro, Y. (2009). Epitopemap-
ping by amide hydrogen/deuterium exchange coupled with immobilization of
antibody, on-line proteolysis, liquid chromatography and mass spectrometry.
Rapid Commun. Mass Spectrom. 23, 639–647.
de Vries, S.J., and Bonvin, A.M. (2008). How proteins get in touch: interface
prediction in the study of biomolecular complexes. Curr. Protein Pept. Sci.
9, 394–406.
Dondoshansky, I., and Wolf, Y. (2002). Blastclust (NCBI Software
Development Toolkit). (Bethesda, MD: NCBI).
Ehlers, M., Fukuyama, H., McGaha, T.L., Aderem, A., and Ravetch, J.V. (2006).
TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and
2b autoantibodies in SLE. J. Exp. Med. 203, 553–561.
Greenbaum, J.A., Andersen, P.H., Blythe, M., Bui, H.H., Cachau, R.E., Crowe,
J., Davies, M., Kolaskar, A.S., Lund, O., Morrison, S., et al. (2007). Towards a
consensus on datasets and evaluation metrics for developing B-cell epitope
prediction tools. J. Mol. Recognit. 20, 75–82.
Hailey, K.L., Li, S., Andersen, M.D., Roy, M., Woods, V.L., Jr., and Jennings,
P.A. (2009). Pro-interleukin (IL)-1beta shares a core region of stability as
compared with mature IL-1beta while maintaining a distinctly different config-
urational landscape: a comparative hydrogen/deuterium exchange mass
spectrometry study. J. Biol. Chem. 284, 26137–26148.
Hamuro, Y., Anand, G.S., Kim, J.S., Juliano, C., Stranz, D.D., Taylor, S.S., and
Woods, V.L., Jr. (2004). Mapping intersubunit interactions of the regulatory
subunit (RIalpha) in the type I holoenzyme of protein kinase A by amide
hydrogen/deuterium exchange mass spectrometry (DXMS). J. Mol. Biol.
340, 1185–1196.
Hopp, T.P., and Woods, K.R. (1981). Prediction of protein antigenic determi-
nants from amino acid sequences. Proc. Natl. Acad. Sci. USA 78, 3824–3828.
Jones, S., and Thornton, J.M. (1997a). Analysis of protein-protein interaction
sites using surface patches. J. Mol. Biol. 272, 121–132.
Jones, S., and Thornton, J.M. (1997b). Prediction of protein-protein interaction
sites using patch analysis. J. Mol. Biol. 272, 133–143.
Kabsch, W., and Sander, C. (1983). Dictionary of protein secondary struc-
ture: pattern recognition of hydrogen-bonded and geometrical features.
Biopolymers 22, 2577–2637.
Keskin, O., Gursoy, A., Ma, B., and Nussinov, R. (2008). Principles of protein-
protein interactions: what are the preferred ways for proteins to interact?
Chem. Rev. 108, 1225–1244.
Kringelum, J.V., Nielsen, M., Padkjær, S.B., and Lund, O. (2013). Structural
analysis of B-cell epitopes in antibody:protein complexes. Mol. Immunol. 53,
24–34.reserved
Structure
Antibody-Specific Epitope MappingKulkarni-Kale, U., Bhosle, S., and Kolaskar, A.S. (2005). CEP: a conformational
epitope prediction server. Nucleic Acids Res. 33 (Web Server issue), W168–
W171.
Kunik, V., and Ofran, Y. (2013). The indistinguishability of epitopes from protein
surface is explained by the distinct binding preferences of each of the six
antigen-binding loops. Protein Eng. Des. Sel. 26, 1–11.
Kunik, V., Ashkenazi, S., and Ofran, Y. (2012a). Paratome: an online tool for
systematic identification of antigen-binding regions in antibodies based on
sequence or structure. Nucleic Acids Res. 40 (Web Server issue), W521–
W524.
Kunik, V., Peters, B., and Ofran, Y. (2012b). Structural consensus among anti-
bodies defines the antigen binding site. PLoS Comput. Biol. 8, e1002388.
Lefranc, M.P., Ehrenmann, F., and Kaas, Q. (2010). IMGT/3Dstructure-DB and
IMGT/DomainGapAlign: a database and a tool for immunoglobulins or anti-
bodies, T cell receptors, MHC, IgSF and MhcSF. Nucleic Acids Res. 38,
D301–D307.
Li, W., and Godzik, A. (2006). Cd-hit: a fast program for clustering and
comparing large sets of protein or nucleotide sequences. Bioinformatics 22,
1658–1659.
Li, S., Tsalkova, T., White, M.A., Mei, F.C., Liu, T., Wang, D., Woods, V.L., Jr.,
and Cheng, X. (2011). Mechanism of intracellular cAMP sensor Epac2 activa-
tion: cAMP-induced conformational changes identified by amide hydrogen/
deuterium exchange mass spectrometry (DXMS). J Biol. Chem. 286, 17889–
17897.
Liang, S.D., Zheng, D.D., Zhang, C., and Zacharias, M. (2009). Prediction
of antigenic epitopes on protein surfaces by consensus scoring. BMC
Bioinformatics 10, 302.
Liang, S.D., Zheng, D.D., Standley, D.M., Yao, B., Zacharias, M., and Zhang,
C. (2010). EPSVR and EPMeta: prediction of antigenic epitopes using support
vector regression and multiple server results. BMC Bioinformatics 11, 381.
Lo Conte, L., Chothia, C., and Janin, J. (1999). The atomic structure of protein-
protein recognition sites. J. Mol. Biol. 285, 2177–2198.
Lollier, V., Denery-Papini, S., Larre´, C., and Tessier, D. (2011). A generic
approach to evaluate how B-cell epitopes are surface-exposed on protein
structures. Mol. Immunol. 48, 577–585.
Malito, E., Faleri, A., Lo Surdo, P., Veggi, D., Maruggi, G., Grassi, E., Cartocci,
E., Bertoldi, I., Genovese, A., Santini, L., et al. (2013). Defining a protective
epitope on factor H binding protein, a key meningococcal virulence factor
and vaccine antigen. Proc. Natl. Acad. Sci. USA 110, 3304–3309.
Matho, M.H., Maybeno, M., Benhnia, M.R., Becker, D., Meng, X., Xiang, Y.,
Crotty, S., Peters, B., and Zajonc, D.M. (2012). Structural and biochemical
characterization of the vaccinia virus envelope protein D8 and its recognition
by the antibody LA5. J. Virol. 86, 8050–8058.
Meng, X., Zhong, Y., Embry, A., Yan, B., Lu, S., Zhong, G., and Xiang, Y. (2011).
Generation and characterization of a large panel of murine monoclonal anti-
bodies against vaccinia virus. Virology 409, 271–279.
Novotny´, J., Handschumacher, M., Haber, E., Bruccoleri, R.E., Carlson, W.B.,
Fanning, D.W., Smith, J.A., and Rose, G.D. (1986). Antigenic determinants in
proteins coincide with surface regions accessible to large probes (antibody
domains). Proc. Natl. Acad. Sci. USA 83, 226–230.
Obungu, V.H., Gelfanova, V., Rathnachalam, R., Bailey, A., Sloan-Lancaster,
J., and Huang, L. (2009). Determination of the mechanism of action of anti-
FasL antibody by epitope mapping and homology modeling. Biochemistry
48, 7251–7260.
Ofran, Y. (2009). Prediction of protein interaction sites. In Computational
Protein-Protein Interactions, R. Nussinov and G. Schreiber, eds. (Boca
Raton, FL: CRC Press), pp. 167–184.
Ofran, Y., and Rost, B. (2003). Analysing six types of protein-protein interfaces.
J. Mol. Biol. 325, 377–387.
Ofran, Y., and Rost, B. (2007). Protein-protein interaction hotspots carved into
sequences. PLoS Comput. Biol. 3, e119.
Pandit, D., Tuske, S.J., Coales, S.J., E, S.Y., Liu, A., Lee, J.E., Morrow, J.A.,
Nemeth, J.F., and Hamuro, Y. (2012). Mapping of discontinuous conforma-Structure 22tional epitopes by amide hydrogen/deuterium exchange mass spectrometry
and computational docking. J. Mol. Recognit. 25, 114–124.
Ponomarenko, J.V., and Bourne, P.E. (2007). Antibody-protein interactions:
benchmark datasets and prediction tools evaluation. BMC Struct. Biol. 7, 64.
Ponomarenko, J., Bui, H.H., Li, W., Fusseder, N., Bourne, P.E., Sette, A., and
Peters, B. (2008). ElliPro: a new structure-based tool for the prediction of anti-
body epitopes. BMC Bioinformatics 9, 514.
Rubinstein, N.D., Mayrose, I., Martz, E., and Pupko, T. (2009a). Epitopia: a
web-server for predicting B-cell epitopes. BMC Bioinformatics 10, 287.
Rubinstein, N.D., Mayrose, I., and Pupko, T. (2009b). A machine-learning
approach for predicting B-cell epitopes. Mol. Immunol. 46, 840–847.
Sali, A., Potterton, L., Yuan, F., van Vlijmen, H., and Karplus, M. (1995).
Evaluation of comparative protein modeling by MODELLER. Proteins 23,
318–326.
Schlessinger, A., Punta, M., Yachdav, G., Kajan, L., and Rost, B. (2009).
Improved disorder prediction by combination of orthogonal approaches.
PLoS ONE 4, e4433.
Sela-Culang, I., Kunik, V., and Ofran, Y. (2013). The structural basis of anti-
body-antigen recognition. Front. Immunol. 4, 302.
Sette, A., Fleri, W., Peters, B., Sathiamurthy, M., Bui, H.H., and Wilson, S.
(2005). A roadmap for the immunomics of category A-C pathogens.
Immunity 22, 155–161.
Sun, J., Wu, D., Xu, T.L., Wang, X.J., Xu, X.L., Tao, L., Li, Y.X., and Cao, Z.W.
(2009). SEPPA: a computational server for spatial epitope prediction of protein
antigens. Nucleic Acids Res. 37 (Web Server issue), W612–W616.
Sun, P., Chen, W., Huang, Y., Wang, H., Ma, Z., and Lv, Y. (2011). Epitope pre-
diction based on random peptide library screening: benchmark dataset and
prediction tools evaluation. Molecules 16, 4971–4993.
Sweredoski, M.J., and Baldi, P. (2008). PEPITO: improved discontinuous
B-cell epitope prediction using multiple distance thresholds and half sphere
exposure. Bioinformatics 24, 1459–1460.
Thornton, J.M., Edwards,M.S., Taylor, W.R., and Barlow, D.J. (1986). Location
of ‘continuous’ antigenic determinants in the protruding regions of proteins.
EMBO J. 5, 409–413.
Vita, R., Zarebski, L., Greenbaum, J.A., Emami, H., Hoof, I., Salimi, N., Damle,
R., Sette, A., and Peters, B. (2010). The immune epitope database 2.0. Nucleic
Acids Res. 38 (Database issue), D854–D862.
Wang, Z., Raifu, M., Howard, M., Smith, L., Hansen, D., Goldsby, R., and
Ratner, D. (2000). Universal PCR amplification of mouse immunoglobulin
gene variable regions: the design of degenerate primers and an assessment
of the effect of DNA polymerase 30 to 50 exonuclease activity. J. Immunol.
Methods 233, 167–177.
Xu, X., Sun, J., Liu, Q., Wang, X., Xu, T., Zhu, R., Wu, D., and Cao, X. (2010).
Evaluation of spatial epitope computational tools based on experimentally-
confirmed dataset for protein antigens. Chin. Sci. Bull. 55, 2169–2174.
Yang, X.D., and Yu, X.L. (2009). An introduction to epitope prediction methods
and software. Rev. Med. Virol. 19, 77–96.
Yao, B., Zheng, D., Liang, S., and Zhang, C. (2013). Conformational B-cell
epitope prediction on antigen protein structures: a review of current algorithms
and comparison with common binding site prediction methods. PLoS ONE 8,
e62249.
Zhang, Z., and Smith, D.L. (1993). Determination of amide hydrogen exchange
bymass spectrometry: a new tool for protein structure elucidation. Protein Sci.
2, 522–531.
Zhang, Q., Willison, L.N., Tripathi, P., Sathe, S.K., Roux, K.H., Emmett, M.R.,
Blakney, G.T., Zhang, H.M., and Marshall, A.G. (2011a). Epitope mapping of
a 95 kDa antigen in complex with antibody by solution-phase amide backbone
hydrogen/deuterium exchange monitored by Fourier transform ion cyclotron
resonance mass spectrometry. Anal. Chem. 83, 7129–7136.
Zhang, W., Xiong, Y., Zhao, M., Zou, H., Ye, X.H., and Liu, J. (2011b).
Prediction of conformational B-cell epitopes from 3D structures by random
forests with a distance-based feature. BMC Bioinformatics 12, 341., 646–657, April 8, 2014 ª2014 Elsevier Ltd All rights reserved 657
